Search

Displaying results 6261 - 6270 of 7017 in total
  1. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. … In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond.

  2. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  3. Drug

    Teprenone

    go.drugbank.com/drugs/DB15955
    Investigational

  4. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  5. Drug

    Edetate disodium anhydrous

    go.drugbank.com/drugs/DB14600
    ApprovedInvestigationalVet approved

    Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.[A204275]

  6. Drug

    4-Methoxyamphetamine

    go.drugbank.com/drugs/DB01472
    ExperimentalIllicit

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  7. Drug

    Itolizumab

    go.drugbank.com/drugs/DB16207
    Investigational

    Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

  8. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  9. Drug

    Procainamide

    go.drugbank.com/drugs/DB01035
    Approved

    A derivative of procaine with less CNS action.

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, MATE 1 Substrates with a Narrow Therapeutic Index
  10. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.